New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Boston Scientific has received FDA approval for the REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease. Bare-metal stents continue to play an important role in the treatment of CAD and represent a significant portion of the global stent market. The company announced CE Mark for the Rebel Stent System in February. The REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium alloy and a customized stent architecture design. The REBEL Stent offers the identical stent platform as the Promus PREMIER Drug-Eluting Stent but without the Everolimus drug.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
09:02 EDTBSXBoston Scientific presents data of Precision Spinal Cord Stimulator system
Subscribe for More Information
December 10, 2014
07:38 EDTBSXBoston Scientific management to meet with Deutsche Bank
Subscribe for More Information
06:01 EDTBSXBoston Scientific implied volatility of 38 at upper end of index mean range
December 9, 2014
10:27 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
December 8, 2014
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 5, 2014
10:44 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
05:54 EDTBSXStocks with implied volatility movement; BSX OPK
Stocks with implied volatility movement; Boston Scientific (BSX) 32, OPKO Health (OPK) 37 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use